CIBC Asset Management Inc Sells 4,667 Shares of IQVIA Holdings Inc. $IQV

CIBC Asset Management Inc lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.0% in the fourth quarter, Holdings Channel reports. The firm owned 232,701 shares of the medical research company’s stock after selling 4,667 shares during the period. CIBC Asset Management Inc’s holdings in IQVIA were worth $52,453,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. acquired a new position in IQVIA during the 4th quarter worth $25,000. Physician Wealth Advisors Inc. lifted its position in IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after acquiring an additional 134 shares during the last quarter. International Assets Investment Management LLC acquired a new position in IQVIA during the 4th quarter worth $27,000. Westside Investment Management Inc. increased its stake in shares of IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after purchasing an additional 101 shares during the period. Finally, Measured Wealth Private Client Group LLC bought a new position in shares of IQVIA in the third quarter worth about $30,000. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. JPMorgan Chase & Co. dropped their price objective on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research note on Friday, February 6th. Morgan Stanley set a $225.00 price objective on shares of IQVIA in a research note on Thursday, May 7th. Jefferies Financial Group lowered their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Royal Bank Of Canada assumed coverage on shares of IQVIA in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective on the stock. Finally, Citigroup lowered their price objective on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, IQVIA presently has a consensus rating of “Buy” and a consensus price target of $224.13.

IQVIA Trading Up 0.8%

Shares of IQVIA stock opened at $182.12 on Thursday. The company’s fifty day simple moving average is $171.35 and its 200-day simple moving average is $195.26. The company has a market cap of $30.40 billion, a price-to-earnings ratio of 22.57, a PEG ratio of 1.73 and a beta of 1.21. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 1 year low of $143.00 and a 1 year high of $247.04.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.IQVIA’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period last year, the business earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 11.58 EPS for the current year.

IQVIA declared that its Board of Directors has approved a stock repurchase program on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its shares are undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.